These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 10710095)
1. Complete regression of hepatocellular carcinoma under tamoxifen. Castéra L; Boige V; Rocher L; Duclos-Vallée JC; Fabre M; Buffet C Am J Gastroenterol; 2000 Mar; 95(3):827-9. PubMed ID: 10710095 [No Abstract] [Full Text] [Related]
2. [Tamoxifen and hepatocarcinoma]. Mondragón Sánchez R Rev Gastroenterol Mex; 1998; 63(3):169. PubMed ID: 10068765 [No Abstract] [Full Text] [Related]
3. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment. Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153 [No Abstract] [Full Text] [Related]
4. Regression of a hepatocellular carcinoma following treatment with octreotide and tamoxifen in a patient with advanced alcoholic cirrhosis. Senturk H; Canbakan B; Cumali R J Gastroenterol Hepatol; 2004 Jun; 19(6):719-20. PubMed ID: 15151636 [No Abstract] [Full Text] [Related]
8. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma. Chow PK Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294 [No Abstract] [Full Text] [Related]
9. Tamoxifen treatment in hepatocellular carcinoma. Farinati F Gastroenterology; 1996 Jul; 111(1):272-4. PubMed ID: 8698220 [No Abstract] [Full Text] [Related]
10. Variant liver estrogen and response to tamoxifen. Villa E; Camellini L; Dugani A; Buttafoco P; Grottola A; Manenti F Gastroenterology; 1996 Jul; 111(1):271-2. PubMed ID: 8698219 [No Abstract] [Full Text] [Related]
11. Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients. García-Leiva J; Gamboa-Domínguez A; Ceron-Lizarraga T; Morales-Espinosa D; Meza-Junco J; Arrieta O Ann Hepatol; 2006; 5(4):263-7. PubMed ID: 17151578 [TBL] [Abstract][Full Text] [Related]
12. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift. Tan CK; Chow PK; Findlay M; Wong C; Machin D J Gastroenterol Hepatol; 2000 Jul; 15(7):725-9. PubMed ID: 10937676 [TBL] [Abstract][Full Text] [Related]
13. [Complete remission of hepatocarcinoma metastasis during palliative treatment with tamoxifen]. Morra A; Sponza M; Stanta G; Urban F; Frezza M Radiol Med; 1998 Sep; 96(3):263-5. PubMed ID: 9850724 [No Abstract] [Full Text] [Related]
14. Re: Liu et al.--Estrogen receptor status in inoperable hepatocellular carcinoma. Chow PK; Hung H; Soo KC Am J Gastroenterol; 2001 Apr; 96(4):1297-8. PubMed ID: 11316190 [No Abstract] [Full Text] [Related]
15. Systemic treatment of hepatocellular carcinoma. Treiber G Dig Dis; 2001; 19(4):311-23. PubMed ID: 11935091 [TBL] [Abstract][Full Text] [Related]
16. [Regression of hepatocellular carcinoma under Tamoxifen: report of one case and review of the literature]. Macaigne G; Auriault ML; Boivin JF; Cheaib S; Chayette C; Deplus R Gastroenterol Clin Biol; 2002 Dec; 26(12):1165-7. PubMed ID: 12520204 [TBL] [Abstract][Full Text] [Related]
17. [Does anti-estrogen therapy after estrogen receptor analysis have value in palliative therapy of hepatocellular carcinoma?]. Kreysel C; Porschen R Z Gastroenterol; 1998 Jul; 36(7):605-7. PubMed ID: 9738309 [No Abstract] [Full Text] [Related]
18. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Gelmann EP Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-65-S1-70. PubMed ID: 9045318 [TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587 [TBL] [Abstract][Full Text] [Related]